



## NEWS RELEASE

### **XDx Announces Name Change to CareDx** *Personalized Treatment Surveillance. Better Outcomes.*

**Brisbane, CA, March 28, 2014**, XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive tests to monitor the immune status in transplant recipients, today announced that it has changed its corporate name to CareDx, Inc., effective immediately. Peter Maag, CareDx, President and CEO, stated “The change in name expands upon our pioneering XDx legacy and reflects our future focus on patient care”.

#### **About CareDx**

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value, non-invasive tests to monitor immune status in transplant recipients with the aim to improve long-term patient outcomes. The company has commercialized AlloMap, which aids clinicians in identifying heart transplant recipients with stable graft function. Some of the AlloMap technology developed by CareDx may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system. For more information, please visit: [www.CareDxInc.com](http://www.CareDxInc.com).

#### **About AlloMap®**

AlloMap Molecular Expression Testing is a non-invasive gene expression test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the XDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.

#### **Contacts**

##### Company

Matthew Meyer  
Chief Business Officer  
CareDx, Inc.  
Tel: 415-287-2393  
[mmeyer@careDxInc.com](mailto:mmeyer@careDxInc.com)